As miR-29 upregulation accompanies the same metabolic disorders, it suggests that (1) miR-29 overexpression triggers metabolic disorders by silencing SIRT-1 and VEGF genes and (2) APDs upregulate miR-29 as part of their mechanism of action, thus enabling the development of metabolic adverse effects. Here, SIRT1 is linked to metabolic disease.